Tables 4 and 5 also list each of the new measures and which ACC/AHA classes of HBP are addressed for each. More detailed descriptive and technical specifications for each measure are listed in Appendix A, which pro- vides additional details for each measure description, numerator, denominator (including denominator exclu- sions and exceptions), rationale for the measure, guide- line recommendations that support the measure, mea- surement period, source of data, and attribution. 1.1. Scope of the Problem Failing to correctly diagnose and control HBP can put people at increased risk for cardiovascular disease, stroke, and renal failure. Recent analyses suggest that >100 million Americans currently have HBP, and the 2011 2014 US National Health and Nutrition Exami- nation Survey estimated that 46% of US adults have An additional 12% of US adults have elevated BP and are at high risk of developing HBP. Among US adults taking antihypertensive medication, 53% have Of US adults with hypertension, 20% were unaware they had the condition.17 In a large cohort study of US adults 45 years of age, the inci- dences of ASCVD and all-cause death were 20.5 and 29.6 per 1000 person-years, respectively, among par- ticipants with ACC/AHA stage 1 HBP who had been recommended to initiate antihypertensive medication, and 22.7 and 32.9 per 1000 person-years, respec- tively, among participants with ACC/AHA stage 2 HBP. Among participants taking antihypertensive medication with above-goal BP (ie, systolic BP 130 mmHg or dia- stolic BP 80 mmHg), the incidences of ASCVD and all-cause death were 33.6 and 42.5 events per 1000 In addition, individuals with HBP face on average nearly $2000 more in annual healthcare expenses than those without HBP.19 Table 3. 